GENETIC VARIANTS AND SERUM PROFILES OF CYTOKINES IN COVID-19 SEVERITY.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
pubmed:
16
11
2022
medline:
31
1
2023
entrez:
15
11
2022
Statut:
ppublish
Résumé
Background: Patients with severe coronavirus disease 2019 (COVID-19) are at an increased risk of acute respiratory distress syndrome and mortality. This is due to the increased levels of pro-inflammatory cytokines that amplify downstream pathways that are controlled by immune regulators. Objective: This study aimed to investigate the association between cytokine genetic variants, cytokine serum levels/profiles, and disease severity in critically and noncritically ill COVID-19 patients. Methods: This cross-sectional study recruited 646 participants who tested positive for severe acute respiratory syndrome coronavirus 2 from six collection sites across the United Arab Emirates. Medical files were accessed to retrieve clinical data. Blood samples were collected from all participants. Patients were divided into two clinical groups, noncritical (n = 453) and critical (n = 193), according to World Health Organization classification guidelines for COVID-19 patients. Cytokine analyses were conducted on serum of a subset of the cohort, specifically on 426 participants (noncritical, 264; critical, 162). Candidate gene analyses of 33 cytokine-related genes (2,836 variants) were extracted from a genome-wide association study to identify genetic variants with pleiotropic effects on a specific cytokine and the severity of COVID-19 disease. Results: Age, body mass index (BMI), and pre-existing medical conditions were found to be significant risk factors that contribute to COVID-19 disease severity. After correcting for age, sex, and BMI, IP-10 ( P < 0.001), IFN ( P = 0.001), IL-6 ( P < 0.001), and CXCL-16 ( P < 0.001) serum levels were significantly higher among critical COVID-19 cases, when compared with noncritically ill patients. To investigate if the genetic variants involved in the serum cytokine levels are associated with COVID-19 severity, we studied several genes. Single nucleotide polymorphisms in IL6 (rs1554606; odd ratio (OR) G = 0.67 [0.66, 0.68]; P = 0.017), IFNG (rs2069718; OR G = 0.63 [0.62, 0.64]; P = 0.001), MIP (rs799187; OR A = 1.69 [1.66, 1.72]; P = 0.034), and CXCL16 (rs8071286; OR A = 1.42 [1.41, 1.44]; P = 0.018) were found to be associated with critically ill patients. Polymorphisms in the CXCL10 , CCL2 , IL1 , CCL7 , and TNF genes were not associated with the COVID-19 critical phenotype. The genotypes of IL-6 (gene, IL6 [7p15.3]) and CXCL-16 (gene, CXCL16 [17p13.2]) were significantly associated with the serum levels of the respective cytokine in critical cases of COVID-19. Conclusion: Data obtained from measuring cytokine levels and genetic variant analyses suggest that IL-6 and CXCL-16 could potentially be used as potential biomarkers for monitoring disease progression of COVID-19 patients. The findings in this study suggest that specific cytokine gene variants correlate with serum levels of the specific cytokine. These genetic variants could be of assistance in the early identification of high-risk patients on admission to the clinic to improve the management of COVID-19 patients and other infectious diseases.
Identifiants
pubmed: 36378234
doi: 10.1097/SHK.0000000000002043
pii: 00024382-202301000-00009
doi:
Substances chimiques
Cytokines
0
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-65Investigateurs
Juan Acuna
(J)
Eman Alefishat
(E)
Ernesto Damiani
(E)
Abdulrahim Sajini
(A)
Andreas Henschel
(A)
Samuel F Feng
(SF)
Ahmed F Yousef
(AF)
Bassam Ali
(B)
Hiba Alhumaidan
(H)
Hala Imambabaccus
(H)
Amirtharaj Francis
(A)
Stefan Weber
(S)
Mohammad Tahseen Al Bataineh
(MTA)
Rabih Halwani
(R)
Rifat Akram Hamoudi
(RA)
Abdulmajeed Alkhajeh
(A)
Bassam H Mahboub
(BH)
Braulio Peramo
(B)
Informations de copyright
Copyright © 2022 by the Shock Society.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069, 2020.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ: COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034, 2020.
Zhao Y, Huang J, Zhang L, Chen S, Gao J, Jiao H: The global transmission of new coronavirus variants. Environ Res 206:112240, 2020.
Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, Salazar-Mather TP, Dumenco L, Savaria MC, Aung SN: Predictors of COVID-19 severity: a literature review. Rev Med Virol 31(1):1–10, 2021.
Domingo P, Mur I, Pomar V, Corominas H, Casademont J, de Benito N: The four horsemen of a viral apocalypse: the pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine 58:102887, 2020.
Alefishat E, Jelinek HF, Mousa M, Tay GK, Alsafar HS: Immune response to SARS-CoV-2 variants: a focus on severity, susceptibility, and preexisting immunity. J Infect Public Health 15:277–288, 2022.
Dorgham K, Quentric P, Gokkaya M, Marot S, Parizot C, Sauce D, Guihot A, Luyt CE, Schmidt M, Mayaux J, et al.: Distinct cytokine profiles associated with COVID-19 severity and mortality. J Allergy Clin Immunol 147(6):2098–2107, 2021.
Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, et al.: On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol 72(7):1059–1063, 2020.
Vardhana SA, Wolchok JD: The many faces of the anti-COVID immune response. J Exp Med 217(6):e20200678, 2020.
Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, François B, Sève P: Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev 19(7):102567, 2020.
Sinha P, Matthay MA, Calfee CS: Is a “cytokine storm” relevant to COVID-19? JAMA Intern Med 180(9):1152–1154, 2020.
Abidi E, El Nekidy WS, Alefishat E, Rahman N, Petroianu GA, El-Lababidi R, Mallat J: Tocilizumab and COVID-19: timing of administration and efficacy. Front Pharmacol 13:825749, 2022.
Que Y, Hu C, Wan K, Hu P, Wang R, Luo J, Li T, Ping R, Hu Q, Sun Y, et al.: Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol 41(2):217–230, 2022.
Severe Covid GG, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernandez J, Prati D, Baselli G, et al.: Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med 383(16):1522–1534, 2020.
Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD, et al.: Genetic mechanisms of critical illness in COVID-19. Nature 591(7848):92–98, 2021.
Banerjee M, Saxena M: Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus. World J Diabetes 5(4):493–504, 2014.
Jiang S, Wang R, Li L, Hong D, Ru R, Rao Y, Miao J, Chen N, Wu X, Ye Z, et al.: Liver injury in critically ill and non-critically ill COVID-19 patients: a multicenter, retrospective, observational study. Front Med (Lausanne) 7:347, 2020.
WHO. Clinical Management of Covid-19—Interim Guidance. Published 2022. Available at: https://www.who.int/publications/i/item/clinical-management-of-covid-19 . Accessed October 24, 2021.
Mousa M, Vurivi H, Kannout H, Uddin M, Alkaabi N, Mahboub B, Tay GK, Alsafar HS, Partnership UC-C: Genome-wide association study of hospitalized COVID-19 patients in the United Arab Emirates. EBioMedicine 74:103695, 2021.
Du Y, Lv Y, Zha W, Zhou N, Hong X: Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism 117:154373, 2021.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et al.: Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130(5):2620–2629, 2020.
Petrey AC, Qeadan F, Middleton EA, Pinchuk IV, Campbell RA, Beswick EJ: Cytokine release syndrome in COVID-19: innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex. J Leukoc Biol 109(1):55–66, 2021.
Kooistra EJ, de Nooijer AH, Claassen WJ, Grondman I, Janssen NA, Netea MG, van de Veerdonk FL, van der Hoeven JG, Kox M, Pickkers P: A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients. Int J Obes (Lond) 45(3):687–694, 2021.
Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, Debnath O, Thürmann L, Kurth F, Völker MT: COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nat Biotechnol 38(8):970–979, 2020.
Fricke-Galindo I, Falfan-Valencia R: Genetics insight for COVID-19 susceptibility and severity: a review. Front Immunol 12:622176, 2021.
Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, et al.: Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181(5):1036–1045.e9, 2020.
Forbester JL, Humphreys IR: Genetic influences on viral-induced cytokine responses in the lung. Mucosal Immunol 14(1):14–25, 2021.
Debnath M, Banerjee M, Berk M: Genetic gateways to COVID-19 infection: implications for risk, severity, and outcomes. FASEB J 34(7):8787–8795, 2020.
Wang X, Sahu KK, Cerny J: Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis 51(3):657–662, 2021.
Yildirim Z, Sahin OS, Yazar S, Bozok Cetintas V: Genetic and epigenetic factors associated with increased severity of Covid-19. Cell Biol Int 45(6):1158–1174, 2021.
Shelton JF, Shastri AJ, Ye C, Weldon CH, Filshtein-Sonmez T, Coker D, Symons A, Esparza-Gordillo J, Aslibekyan S, et al; 23andMe COVID-19 Team.: Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat Genet 53(6):801–808, 2021.